Nanotechnology-Based Inhalation Approach for Lung Cancer

Ever since the success of producing inhalable insulin, drug delivery via pulmonary administration has been an intriguing way to treat chronic disorders. Pulmonary delivery system for nanotechnology is a relatively recent approach, especially when related to lung cancer therapy. The therapeutic ratio is increased by inhalation delivery, which delivers a high dose of the drug directly to the lungs without damaging other body organs. Despite extensive studies into targeted delivery and specific molecular inhibitors (gene delivery), cytotoxic drug delivery via inhalation is still considered a critical component of lung cancer treatment. Nanotechnology-based inhalation chemotherapy has been proven to be practical and more successful than conventional chemotherapy, with fewer adverse effects. Many nanocarriers have recently been studied for inhalation treatments of lung cancer, including liposomes, polymeric micelles, polymeric NPs, solid lipid NPs, and inorganic NPs. The potential for NPs-based local lung cancer targeting via inhalation, as well as the challenges that come with it, are explored here.